Aspergen Inc. ( A joint venture between Cipla and Kemwell Biopharma) is an emerging biopharmaceutical company, specializing in the development, manufacturing, and commercialization of biologics and biosimilar products. With a team of experienced scientists, researchers, and industry professionals, we are at the forefront of the novel biologics, ADC & biosimilars revolution, striving to address the unmet medical needs of patients worldwide.

Cipla supports the clinical development, regulatory, IP, and commercialization with a strong front-end presence in India + EM markets. Has launched multiple innovative biologics and biosimilars by partnering with innovator companies in various markets, and currently caters to 78 markets around the world.

Kemwell provides end-to-end manufacturing support for the mAbs/complex biologics and has supported multiple IND filings for novel biologics to US biotechs. Kemwell's biologics DP facility is approved by the USFDA.